Therefore, over time, the targets 5-HT1B/D (triptans) and cyclooxygenase-1 (COX1) (NSAIDs) will be gradually abandoned since CGRP, whose use in migraine prevention has not shown particular AEs or tachyphylaxis, as reported in randomized controlled trials. This evidence concerns the gene HTR1B and migraine disorder.